Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 6/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475256 | 1.00 | FAAH (0.45) | FAAHTRPV1MEN1KMT2ACTSK | |
| SCHEMBL6482748 | 1.00 | FAAH (0.45) | FAAHTRPV1MEN1KMT2ACTSK | |
| SCHEMBL6483536 | 0.99 | FAAH (0.43) | FAAHTRPV1MEN1KMT2ACTSK | |
| SCHEMBL6481332 | 0.90 | MEN1 (0.43) | FAAHTRPV1MEN1KMT2ACTSK | |
| SCHEMBL6483593 | 0.90 | MEN1 (0.43) | FAAHTRPV1MEN1KMT2ACTSK | |
| SCHEMBL6475365 | 0.90 | MEN1 (0.43) | FAAHTRPV1MEN1KMT2ACTSK | |
| SCHEMBL6475580 | 0.88 | MEN1 (0.41) | FAAHTRPV1MEN1KMT2ACTSK | |
| SCHEMBL6475744 | 0.86 | POLB (0.39) | MEN1KMT2ANPSR1CNR2 | |
| SCHEMBL8697428 | 0.86 | GPR88 (0.47) | FAAHTRPV1MEN1KMT2ACTSK | |
| SCHEMBL8701623 | 0.86 | GPR88 (0.47) | FAAHTRPV1MEN1KMT2ACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939888-B2 | 1-H-3-arylpirrolidine-2,4-dione derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-09-06 | — | — | US | disclosed |
| US-20040019061-A1 | 1-H-3-arylpirrolidine-2,4-dione derivatives | FISCHER REINER (DE) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019061-A1 | 1-H-3-arylpirrolidine-2,4-dione derivatives | PRXL2A, DDT, CYP4B1 | FAAH 1329/4885TRPV1 2340/4885MEN1 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.